A Study to Assess the Potential for Airway Sensitivity Reactions With Propellants HFA-152a (Test) and HFA-134a (Reference) Administered Via Pressurized Inhalers in Adults With Mild Asthma

Inclusion Criteria: Participants are eligible to be included in the study if all the following criteria apply: * Male or female; females may be of childbearing potential, of nonchildbearing potential, or postmenopausal. * Participant must be 18 to 45 years of age inclusive, at the time of screening. * Confirmed diagnosis of asthma: documented, established diagnosis of asthma for at least 6 months. * Receiving 1 of the following asthma treatments, at a stable dose, for at least 12 weeks prior to the screening visit and is anticipated to remain stable for the duration of the study: * As needed short-acting beta-agonists (SABA) only * As needed SABA plus low-dose Inhaled corticosteroids (ICS) (defined as 100-250 µg/day fluticasone propionate or equivalent taken whenever SABA is taken). * Daily maintenance low-dose ICS, plus as needed SABA or ICS-SABA single inhaler combination therapy * Low dose combination single inhaler ICS-formoterol or single inhaler ICS-SABA as needed for symptom relief (and if needed, before exercise) * Leukotriene receptor antagonist (LTRAs) in combination with any of the above therapies * Asthma Control Questionnaire (ACQ)-6 score \<1.5 at screening and Day -1. * No severe asthma exacerbations within 6 months prior to screening and ≤1 severe exacerbation during the 12 months prior to screening. * Lung function: subjects with a pre-bronchodilator FEV1 ≥60% predicted at Screening and Day-1. * A female participant is eligible to participate if …